The evolving role of circulating tumor cells in the personalized management of breast cancer: From enumeration to molecular characterization

Current Breast Cancer Reports

Volumn 6, Issue 3, 2014, Pages 146-153

  Sarangi, Sasmit ^a   Mosalpuria, Kailash ^b   Higgins, Michaela J ^a   Bardia, Aditya ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Breast cancer; Circulating tumor cells; Molecular characterization; Personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER THERAPY; CANCER TISSUE; CIRCULATING TUMOR CELL; EARLY DIAGNOSIS; HUMAN; PERSONALIZED MEDICINE; TREATMENT RESPONSE;

EID: 84906936107     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-014-0149-9     Document Type: Article

References (53)

1. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res. 1999;5:1950-60.
2. Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A. 1998;95:4589-94.
3. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-91.
4. Peeters DJ, De Laere B, Van den Eynden GG, et al. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from Cell Search enriched blood samples using dielectrophoretic cell sorting. Br J Cancer. 2013;108:1358-67.
5. Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000;156:57-63.
6. Aerts J, Wynendaele W, Paridaens R, et al. A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol. 2001;12:39-46.
7. Ko Y, Klinz M, Totzke G, Gouni-Berthold I, Sachinidis A, Vetter H. Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood. Clin Cancer Res. 1998;4:2141-6.
8. Krivacic RT, Ladanyi A, Curry DN, et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A. 2004;101:10501-4.
9. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235-9.
10. • Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580-4. This study reports a novel method of identify mesenchymal CTCs in breast cancer and correlates them with disease progression.
11. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14 Pt 1):4218-24.
12. • Pierga JY, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23:618-24. This prospective series of patients confirms the independent prognostic impact of CTCs and compares them with established tumor markers in metastatic breast cancer.
13. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27:5153-9.
14. • Bardia A, Huang P, Zhang Z, Sokoll L, Ingle JN, Carey LA, et al. Circulating tumor cells (CTCs) and CA27.29 as predictors of outcome in metastatic breast cancer (MBC) patients in the prospective TBCRC 005 Biomarker study. J Clin Oncol. 2010;28(Suppl):1001. [Abstract]. Clinical trial demonstrated that change in CA2729 change from baseline to week 3-4 post-therapy was independently and more strongly associated with progression of disease compared with change in CTC count.
15. Giordano A, Giuliano M, De Laurentiis M, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 2012;23:1144-50.
16. Wallwiener M, Hartkopf AD, Baccelli I, et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat. 2013;137:503-10.
17. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells vs imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403-9.
18. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010;21:33-9.
19. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456-66.
20. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-312.
21. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12:R75.
22. • Smerage JB, Barlow WE, Hayes DF, et al. SWOG S0500 - a randomized phase III trial to test the strategy of changing therapy vs maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. Presented at San Antonio Breast Cancer Symposium, December, 2013. Clinical trial demonstrated that changing therapy based on earlier detection of elevated CTC count after therapy does not result in superior outcomes.
23. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601-8.
24. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16:2634-45.
25. Sieuwerts AM, Mostert B, Bolt-de Vries J, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res. 2011;17:3600-18.
26. Somlo G, Lau SK, Frankel P, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011;128:155-63.
27. Aktas B, Muller V, Tewes M, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol. 2011;122:356-60.
28. Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11:R59.
29. Hayes DF, Walker TM, Singh B, et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol. 2002;21:1111-7.
30. Wulfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006;12:1715-20.
31. Flores LM, Kindelberger DW, Ligon AH, et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer. 2010;102:1495-502.
32. Tewes M, Aktas B, Welt A, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2009;115:581-90.
33. DETECT III - A multicenter, phase III study to compare standard therapy +/-lapatinib in HER2-ve MBC-patients with HER2+ve CTCs [database on the Internet]. Available at: http://clinicaltrials.gov/show/NCT01619111. Accessed Dec 30, 2013.
34. Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, et al. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle. 2013;12:2132-43.
35. Hou HW, Warkiani ME, Khoo BL, et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013;3:1259.
36. Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5, 179ra47.
37. • Schneck H, Blassl C, Meier-Stiegen F, et al. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2013;7:976-86. This study reports a new method to molecularly characterize and identify actionable mutations in isolated CTCs.
38. Characterization of circulating tumor cells (CTCs) to direct preoperative and systemic therapy in patients with locally advanced or metastatic stage IV breast cancer [database on the Internet]. Available at: http://clinicaltrials. gov/show/NCT01048918. Accessed Dec 30, 2013.
39. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant vs anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386-95.
40. Characterization of circulating tumor cells (CTC) from patients with metastatic breast cancer using the CTC-Endocrine Therapy Index (COMETI P2) [database on the Internet]. Available at: http://clinicaltrials.gov/show/ NCT01701050. Accessed Jan 16, 2014.
41. Krishnamurthy S, Cristofanilli M, Singh B, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010;116:3330-7.
42. Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13:688-95.
43. Coumans FA, Siesling S, Terstappen LW. Detection of cancer before distant metastasis. BMC Cancer. 2013;13:283.
44. Fischer JC, Niederacher D, Topp SA, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A. 2013;110:16580-5.
45. Circulating tumor cells (CTCs): a potential screening test for clinically undetectable breast carcinoma [database on the Internet]. Available at: http://clinicaltrials.gov/show/NCT01322750. Accessed Dec 30, 2013.
46. Nakagawa T, Martinez SR, Goto Y, et al. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res. 2007;13:4105-10.
47. • Georgoulias V, Bozionelou V, Agelaki S, et al. Trastuzumab decreases the incidence of clinical relapses in patientswith early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol. 2012;23:1744-50. This Phase-II study demonstrates the ability of trastuzumab to effectively eliminate HER2+ CTCs, in patients with HER2- primary tumors. Trastuzumab treated patients had a longer DFS and reduced number of relapses.
48. Efficacy study of Herceptin to treat HER2-negative CTC breast cancer (TREAT-CTC) [database on the Internet]. Available at: http://clinicaltrials.gov/ show/NCT01548677. Accessed Dec 30, 2013.
49. Zhang L, Ridgway LD, Wetzel MD, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013;5, 180ra48.
50. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22:194-207.
51. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012;14:R15.
52. • Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199-209. This prospective study shows a higher sensitivity of detection of circulating tumor DNA in comparison to CTCs, in selected patients with specific mutations.
53. • Higgins MJ, Jelovac D, Barnathan E, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012;18:3462-9. This study reports a novel technique to identify specific cancermutations from a blood sample, by detecting circulating tumor DNA.